Jeffrey S. Ginsberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeffrey S. Ginsberg has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Jack Hirsh
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
2 shared publications - Noel C. Chan
Division of Haematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
2 shared publications Shannon M. Bates
2 shared publicationsBetsy MacKinnon
1 shared publicationClive Kearon
1 shared publication- David Robert Anderson
Dalhousie University, Halifax, Nova Scotia, Canada
1 shared publication
Latest Publications
- Open Access
- 1 August 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (8) , 2467
Prevention of Venous Thromboembolism in 2020 and Beyond
Venous thromboembolism (VTE) is the third most common cause of vascular mortality worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In this review, we discuss how an understanding of VTE epidemiology and the results of thromboprophylaxis trials have shaped the current approach to VTE prevention. We will discuss modern thromboprophylaxis as it pertains to genetic risk factors, exogenous hormonal therapies, pregnancy, surgery, medical hospitalization, cancer, and what is known thus far about VTE in COVID-19 infection.
- 1 August 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (8) , 2467
Open AccessPrevention of Venous Thromboembolism in 2020 and Beyond
Venous thromboembolism (VTE) is the third most common cause of vascular mortality worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In this review, we discuss how an understanding of VTE epidemiology and the results of thromboprophylaxis trials have shaped the current approach to VTE prevention. We will discuss modern thromboprophylaxis as it pertains to genetic risk factors, exogenous hormonal therapies, pregnancy, surgery, medical hospitalization, cancer, and what is known thus far about VTE in COVID-19 infection.
- Open Access
- 20 April 2017
- Published by Springer Nature in BMC Public Health
- Vol. 17 (1) , 1-10
The development and validation of an instrument to measure the quality of health research reports in the lay media
The media serves as an important link between medical research, as reported in scholarly sources, and the public and has the potential to act as a powerful tool to improve public health. However, concerns about the reliability of health research reports have been raised. Tools to monitor the quality of health research reporting in the media are needed to identify areas of weakness in health research reporting and to subsequently work towards the efficient use of the lay media as a public health tool through which the public’s health behaviors can be improved. We developed the Quality Index for health-related Media Reports (QIMR) as a tool to monitor the quality of health research reports in the lay media. The tool was developed according to themes generated from interviews with health journalists and researchers. Item and domain characteristics and scale reliability were assessed. The scale was correlated with a global quality assessment score and media report word count to provide evidence towards its construct validity. The items and domains of the QIMR demonstrated acceptable validity and reliability. Items from the ‘validity’ domain were negatively skewed, suggesting possible floor effect. These items were not eliminated due to acceptable content and face validity. QIMR total scores produced a strong correlation with raters’ global assessment and a moderate correlation with media report word count, providing evidence towards the construct validity of the instrument. The results of this investigation indicate that QIMR can adequately measure the quality of health research reports, with acceptable reliability and validity.
- 20 April 2017
- Published by Springer Nature in BMC Public Health
- Vol. 17 (1) , 1-10
Open AccessThe development and validation of an instrument to measure the quality of health research reports in the lay media
The media serves as an important link between medical research, as reported in scholarly sources, and the public and has the potential to act as a powerful tool to improve public health. However, concerns about the reliability of health research reports have been raised. Tools to monitor the quality of health research reporting in the media are needed to identify areas of weakness in health research reporting and to subsequently work towards the efficient use of the lay media as a public health tool through which the public’s health behaviors can be improved. We developed the Quality Index for health-related Media Reports (QIMR) as a tool to monitor the quality of health research reports in the lay media. The tool was developed according to themes generated from interviews with health journalists and researchers. Item and domain characteristics and scale reliability were assessed. The scale was correlated with a global quality assessment score and media report word count to provide evidence towards its construct validity. The items and domains of the QIMR demonstrated acceptable validity and reliability. Items from the ‘validity’ domain were negatively skewed, suggesting possible floor effect. These items were not eliminated due to acceptable content and face validity. QIMR total scores produced a strong correlation with raters’ global assessment and a moderate correlation with media report word count, providing evidence towards the construct validity of the instrument. The results of this investigation indicate that QIMR can adequately measure the quality of health research reports, with acceptable reliability and validity.
- 18 November 2014
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 40 (2) , 231-239
A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal
In the last decade, major advances in venous thromboembolism (VTE) prophylaxis in orthopaedic surgery have included the development of new anticoagulants that are poised to replace low molecular weight heparins (LMWHs) and improvements in operative and perioperative care that have likely led to a decline in the rates of symptomatic VTE and mortality independent of anticoagulant use. A systematic review of the literature was performed to identify phase III randomized controlled trials of VTE prevention that compared new anticoagulants (fondaparinux, rivaroxaban, dabigatran, apixaban) with LMWH (enoxaparin) in major elective orthopaedic surgery. Our aims were to obtain best estimates of the rates of patient important events (symptomatic VTE, mortality, and bleeding) in contemporary trials of VTE prevention, and to consider the implications of these contemporary rates for clinical practice and future research. Fourteen studies, which enrolled 40,285 patients, were included in the analyses. The combined median rates (ranges) for all five anticoagulants for symptomatic VTE and mortality to the end of follow-up were 0.99 % (0.15–2.58 %) and 0.26 % (0–0.92 %) respectively, whereas the median rate (range) of clinically important bleeding was 3.44 % (2.25–7.74 %). In contemporary trials of anticoagulants, the rates of symptomatic VTE and mortality are low, but the rates of clinically important post-operative bleeding remain relatively high. Based on these results, we propose that approaches that minimize bleeding without substantially reducing efficacy merit investigation, particularly if improvement in surgical and perioperative care have also resulted in falling baseline patient important VTE rates independent of anticoagulant use.
- 18 November 2014
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 40 (2) , 231-239
A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal
In the last decade, major advances in venous thromboembolism (VTE) prophylaxis in orthopaedic surgery have included the development of new anticoagulants that are poised to replace low molecular weight heparins (LMWHs) and improvements in operative and perioperative care that have likely led to a decline in the rates of symptomatic VTE and mortality independent of anticoagulant use. A systematic review of the literature was performed to identify phase III randomized controlled trials of VTE prevention that compared new anticoagulants (fondaparinux, rivaroxaban, dabigatran, apixaban) with LMWH (enoxaparin) in major elective orthopaedic surgery. Our aims were to obtain best estimates of the rates of patient important events (symptomatic VTE, mortality, and bleeding) in contemporary trials of VTE prevention, and to consider the implications of these contemporary rates for clinical practice and future research. Fourteen studies, which enrolled 40,285 patients, were included in the analyses. The combined median rates (ranges) for all five anticoagulants for symptomatic VTE and mortality to the end of follow-up were 0.99 % (0.15–2.58 %) and 0.26 % (0–0.92 %) respectively, whereas the median rate (range) of clinically important bleeding was 3.44 % (2.25–7.74 %). In contemporary trials of anticoagulants, the rates of symptomatic VTE and mortality are low, but the rates of clinically important post-operative bleeding remain relatively high. Based on these results, we propose that approaches that minimize bleeding without substantially reducing efficacy merit investigation, particularly if improvement in surgical and perioperative care have also resulted in falling baseline patient important VTE rates independent of anticoagulant use.
- Open Access
- 24 July 2007
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 7 (1) , 21
Effectiveness of compression stockings to prevent the post-thrombotic syndrome (The SOX Trial and Bio-SOX biomarker substudy): a randomized controlled trial
Post thrombotic syndrome (PTS) is a burdensome and costly complication of deep venous thrombosis (DVT) that develops in 20–40% of patients within 1–2 years after symptomatic DVT. Affected patients have chronic leg pain and swelling and may develop ulcers. Venous valve disruption from the thrombus itself or thrombus-associated mediators of inflammation is considered to be a key initiating event for the development of venous hypertension that often underlies PTS. As existing treatments for PTS are extremely limited, strategies that focus on preventing the development of PTS in patients with DVT are more likely to be effective and cost-effective in reducing its burden. Elastic compression stockings (ECS) could be helpful in preventing PTS; however, data on their effectiveness are scarce and conflicting.
- 24 July 2007
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 7 (1) , 21
Open AccessEffectiveness of compression stockings to prevent the post-thrombotic syndrome (The SOX Trial and Bio-SOX biomarker substudy): a randomized controlled trial
Post thrombotic syndrome (PTS) is a burdensome and costly complication of deep venous thrombosis (DVT) that develops in 20–40% of patients within 1–2 years after symptomatic DVT. Affected patients have chronic leg pain and swelling and may develop ulcers. Venous valve disruption from the thrombus itself or thrombus-associated mediators of inflammation is considered to be a key initiating event for the development of venous hypertension that often underlies PTS. As existing treatments for PTS are extremely limited, strategies that focus on preventing the development of PTS in patients with DVT are more likely to be effective and cost-effective in reducing its burden. Elastic compression stockings (ECS) could be helpful in preventing PTS; however, data on their effectiveness are scarce and conflicting.
- Open Access
- 24 March 2003
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 163 (6) , 694-698
Anticoagulation of Pregnant Women With Mechanical Heart Valves
The management of pregnant women with mechanical heart valves is challenging. Recently, based on small numbers of patients and poor-quality data, correspondence from Aventis Pharmaceuticals Inc has described treatment "failures" and concerns about teratogenicity with the use of the low-molecular-weight heparin (LMWH) enoxaparin. The company issued a "Warning" that enoxaparin should not be used in patients with prosthetic heart valves and a "Precaution" about potential teratogenicity. This has created a huge problem for physicians managing pregnant women with prosthetic heart valves because the alternatives, unfractionated heparin and warfarin, are problematic. There have been case reports of failures #1including death from thrombosed valves) with unfractionated heparin, whereas the package insert for warfarin states that the drug is contraindicated during pregnancy because of potential teratogenicity. Initially, LMWHs appeared suitable for pregnant patients with prosthetic heart valves. Unfortunately, the company correspondence, presumably supported by the Food and Drug Administration (FDA), raises medicolegal concerns with use of any LMWH. We believe that pharmaceutical companies and the FDA should not endorse scientifically unsupported claims that eliminate acceptable therapeutic options. This correspondence has created considerable confusion among patients and treating physicians and is likely to lead to frivolous lawsuits and preclude the performance of properly designed trials in pregnant women. We believe a consensus conference among experts in the field to identify key unresolved issues and a commitment by the FDA and industry to perform appropriate studies are now critical.
- 24 March 2003
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 163 (6) , 694-698
Open AccessAnticoagulation of Pregnant Women With Mechanical Heart Valves
The management of pregnant women with mechanical heart valves is challenging. Recently, based on small numbers of patients and poor-quality data, correspondence from Aventis Pharmaceuticals Inc has described treatment "failures" and concerns about teratogenicity with the use of the low-molecular-weight heparin (LMWH) enoxaparin. The company issued a "Warning" that enoxaparin should not be used in patients with prosthetic heart valves and a "Precaution" about potential teratogenicity. This has created a huge problem for physicians managing pregnant women with prosthetic heart valves because the alternatives, unfractionated heparin and warfarin, are problematic. There have been case reports of failures #1including death from thrombosed valves) with unfractionated heparin, whereas the package insert for warfarin states that the drug is contraindicated during pregnancy because of potential teratogenicity. Initially, LMWHs appeared suitable for pregnant patients with prosthetic heart valves. Unfortunately, the company correspondence, presumably supported by the Food and Drug Administration (FDA), raises medicolegal concerns with use of any LMWH. We believe that pharmaceutical companies and the FDA should not endorse scientifically unsupported claims that eliminate acceptable therapeutic options. This correspondence has created considerable confusion among patients and treating physicians and is likely to lead to frivolous lawsuits and preclude the performance of properly designed trials in pregnant women. We believe a consensus conference among experts in the field to identify key unresolved issues and a commitment by the FDA and industry to perform appropriate studies are now critical.
- 1 September 2002
- Published by Elsevier in Thrombosis Research
- Vol. 107 (6) , 287-290
Low-dose warfarin in rehabilitating stroke survivors
- 1 September 2002
- Published by Elsevier in Thrombosis Research
- Vol. 107 (6) , 287-290
Low-dose warfarin in rehabilitating stroke survivors
- Open Access
- 28 January 2002
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 162 (2) , 217-220
The Sensitivity and Specificity of a Red Blood Cell Agglutination D-Dimer Assay for Venous Thromboembolism When Performed on Venous Blood
D DIMER is a fibrin degradation product formed by the enzymatic activity of plasmin on cross-linked fibrin polymers. Plasma levels can be measured and are useful in patients who present with symptoms of pulmonary embolism (PE) or deep vein thrombosis (DVT),1,2 because negative test results (below a predefined cut point) rule out the likelihood of these diseases.
- 28 January 2002
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 162 (2) , 217-220
Open AccessThe Sensitivity and Specificity of a Red Blood Cell Agglutination D-Dimer Assay for Venous Thromboembolism When Performed on Venous Blood
D DIMER is a fibrin degradation product formed by the enzymatic activity of plasmin on cross-linked fibrin polymers. Plasma levels can be measured and are useful in patients who present with symptoms of pulmonary embolism (PE) or deep vein thrombosis (DVT),1,2 because negative test results (below a predefined cut point) rule out the likelihood of these diseases.